Astrazeneca (AZN) EBIAT (2016 - 2026)

Astrazeneca has reported EBIAT over the past 16 years, most recently at $3.1 billion for Q1 2026.

For Q1 2026, EBIAT rose 5.48% year-over-year to $3.1 billion; the TTM value through Mar 2026 reached $10.4 billion, up 33.55%, while the annual FY2025 figure was $10.2 billion, 45.33% up from the prior year.
EBIAT for Q1 2026 was $3.1 billion at Astrazeneca, up from $2.3 billion in the prior quarter.
Over five years, EBIAT peaked at $3.1 billion in Q1 2026 and troughed at $360.0 million in Q2 2022.
A 5-year average of $1.7 billion and a median of $1.8 billion in 2023 define the central range for EBIAT.
Biggest five-year swings in EBIAT: crashed 68.56% in 2022 and later surged 405.56% in 2023.
Year by year, EBIAT stood at $902.0 million in 2022, then rose by 6.32% to $959.0 million in 2023, then soared by 56.41% to $1.5 billion in 2024, then surged by 55.27% to $2.3 billion in 2025, then skyrocketed by 32.29% to $3.1 billion in 2026.
Business Quant data shows EBIAT for AZN at $3.1 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.5 billion in Q3 2025.

Peer Comparison